CATALYSTInvesting.com • 22h ago
HeartBeam stock soars on FDA breakthrough designationInvesting.com report covering Heartbeam Inc. (BEAT) market action, institutional positioning, and fundamental catalysts.
Why BEAT Stock dropped -25.64% Today — RQD Quant Desk Flash
$0.41 -25.64% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $0.39
Heartbeam Inc. (BEAT) carries a Roarable Rating of D- (Sell) with 42/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • SELL / AVOID
Cap $31.0M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on BEAT Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is BEAT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Heartbeam Inc. (NASDAQ: BEAT) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 42/100 at a spot price of $0.41 (-25.64% 1D, market cap $31.0M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 11/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, BEAT ranks #429 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does BEAT compare to DRIO and NEPH in the Health Care sector?
▼
Within the Health Care sector (Medical/Dental Instruments), BEAT carries a Roarable D- (42/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, DRIO (DarioHealth Corp.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $29.4M) and NEPH (Nephros Inc.) posts a C- grade (59/100 RQD, P/E 29.8x, ROIC 18.9%, cap $34.5M). Among the 5-stock peer group, NEPH leads on earnings multiple (29.8x) while NEPH leads on capital efficiency (18.9% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for BEAT?
▼
Per BEAT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001779372), Heartbeam Inc. generated $59.2M in revenue (+6.3% YoY), -$21.0M in net income, and -$14.6M in free cash flow against $5.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $0.39 (-4.81%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (42/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.0% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D-
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D- · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE-7.3% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BEAT)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (42/100 Composite)
🔍 WHY BEAT SCORES 42/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+11/20 pts (26% of score)
20D Institutional Volume Accumulation (±12.5% realized swing band)
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (24% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$0.40+2.5% Next Q
34
Q2 (-2Q)Grade E$0.41-2.4% Next Q
37
Q3 (-1Q)Grade E$0.40+2.5% Next Q
39
CurrentGrade D-$0.41-7% Hist 90D α
42
Trajectory: E (34) → D- (42)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a BEAT Turnaround Squeeze
While BEAT currently carries a cautious 42/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.45) and Max Pain ($0.43) forces dealer call-delta covering toward $4.20.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $BEAT• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “BEAT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why BEAT Stock dropped -25.64% Today — RQD Quant Desk Flash
Heartbeam Inc. (BEAT) dropped -25.64% to $0.41, trading at 2% of its 52-week range ($0.35 – $4). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 2% of its 52-week range ($0.35 – $4) with RSI-14 at 62.8 (BULLISH MOMENTUM).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $0.41 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live BEAT Headlines & Catalysts
CATALYSTStocktwits • 1d ago
HeartBeam Inc (BEAT) Profile, Company FAQs & Facts, Industry, Sector, Employee StrengthStocktwits report covering Heartbeam Inc. (BEAT) market action, institutional positioning, and fundamental catalysts.
MARKET WIREChartMill • 1d ago
Monday's session: gap up and gap down stocksChartMill report covering Heartbeam Inc. (BEAT) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 1d ago
HeartBeam Receives FDA Breakthrough Device Designation for Heart Attack AssessmentYahoo Finance report covering Heartbeam Inc. (BEAT) market action, institutional positioning, and fundamental catalysts.
CATALYSTwww.marketscreener.com • 1d ago
3 Stocks BEAT, MOBX, PRSO Now: FDA Breakthrough, Rare Earths and Military Drones Drive Catalystswww.marketscreener.com report covering Heartbeam Inc. (BEAT) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
FDA grants HeartBeam technology a breakthrough designation for assessing suspected heart attacks outside hospitals.Stock Titan report covering Heartbeam Inc. (BEAT) market action, institutional positioning, and fundamental catalysts.
MARKET WIREInvesting.com • 1d ago
Why is Heartbeam stock surging today?Investing.com report covering Heartbeam Inc. (BEAT) market action, institutional positioning, and fundamental catalysts.
MARKET WIREInvesting.com • 1d ago
Heartbeam stock rating held at Neutral by H.C. Wainwright on FDA newsInvesting.com report covering Heartbeam Inc. (BEAT) market action, institutional positioning, and fundamental catalysts.
CATALYSTYahoo • 1d ago
HeartBeam Announces Positive Heart Attack Pilot Study Results at TCT 2026: Patient-Recorded 3D ECG Shown to Be as Accurate as Standard 12-Lead ECGSANTA CLARA, Calif., November 02, 2026--HeartBeam Announces Positive Heart Attack Pilot Study Results at TCT 2026: Patient-Recorded 3D ECG Shown to be as Accurate as Standard 12-Lead ECG
MARKET WIREChartMill • 5d ago
Top US Stock Movers in Today's SessionToday's US session featured double-digit moves, with KPTI up 59.38% and JDZG down 77.87% among the largest percentage swings.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BEAT)
- ✓Walkthrough of BEAT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
BEAT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -51.19%📐 HORIZONTAL RANGE
2026-11-03O $0.54H $0.55L $0.41C $0.41VOL 1.70M
RES: $0.95SUP: $0.27SMA50: $0.45SMA200: $0.85
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
BEAT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth
vs. +6.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on BEAT today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for BEAT. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for BEAT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BEAT)
Health Care Rank #429 of 1015
⚔️ DRIO vs BEAT Full Matrix →
1. Head-to-Head Health Care Peer Comparison (BEAT vs. DRIO, NEPH, TELA, PLRZ)
Industry: Medical/Dental Instruments (120 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, Heartbeam Inc. (BEAT) ranks #429 by composite RQD confidence (42/100, grade D-) and #792 by equity capitalization ($31.0M). Within this direct 5-issuer industry benchmark cohort, NEPH leads on earnings valuation at 29.8x trailing P/E, while NEPH leads on capital efficiency and profitability with 18.9% ROIC and 61.9% gross margin. NEPH currently holds the highest overall quantitative score in the immediate peer group at 59/100 (C-) compared with BEAT at 42/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| BEAT
ACTIVE
Heartbeam Inc. | D- | 42/100 | — | — | -35.0% | -25.64% | $31.0M | Benchmark Subject |
| DRIO DarioHealth Corp. | E | 33/100 | — | 56.6% | -35.0% | +1.00% | $29.4M | /drio-vs-beat → |
| NEPH Nephros Inc. | C- | 59/100 | 29.8x | 61.9% | 18.9% | +2.21% | $34.5M | /neph-vs-beat → |
| TELA TELA Bio Inc. | D- | 35/100 | — | 67.7% | -35.0% | -1.33% | $36.6M | /tela-vs-beat → |
| PLRZ Polyrizon Ltd. | E | 34/100 | — | — | -25.1% | +4.74% | $26.1M | /plrz-vs-beat → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001779372 ↗In its most recent audited fiscal period (FY2025, filed 2025-12-31), Heartbeam Inc. (BEAT) reported GAAP revenue of $59.2M (+6.3% vs. FY2024 revenue of $55.7M , and +38.0% cumulative change since FY2023) , GAAP net income of -$21.0M, operating cash flow of -$14.0M, and free cash flow of -$14.6M (+0.6% YoY). On the balance sheet, BEAT closed FY2025 with $5.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $59.2M | -$21.0M | -$14.0M | -$14.6M | $5.8M | — |
| FY2024 (FY) | 2024-12-31 | $55.7M | -$19.4M | -$14.5M | -$14.7M | $3.3M | — |
| FY2023 (FY) | 2023-12-31 | $42.9M | -$14.6M | -$12.1M | -$12.1M | — | — |
3. BEAT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs BEAT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Heartbeam Inc. (NASDAQ: BEAT) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 42/100 at a spot price of $0.41 (-25.64% 1D, market cap $31.0M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 11/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, BEAT ranks #429 in composite RQD confidence.
How does BEAT compare to DRIO and NEPH in the Health Care sector?
Within the Health Care sector (Medical/Dental Instruments), BEAT carries a Roarable D- (42/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, DRIO (DarioHealth Corp.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $29.4M) and NEPH (Nephros Inc.) posts a C- grade (59/100 RQD, P/E 29.8x, ROIC 18.9%, cap $34.5M). Among the 5-stock peer group, NEPH leads on earnings multiple (29.8x) while NEPH leads on capital efficiency (18.9% ROIC).
What are the biggest fundamental strengths and SEC risk factors for BEAT?
Per BEAT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001779372), Heartbeam Inc. generated $59.2M in revenue (+6.3% YoY), -$21.0M in net income, and -$14.6M in free cash flow against $5.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Where is BEAT trading relative to its 50-day, 200-day, and 52-week technical levels?
BEAT last traded at $0.41 (-25.64% on volume of 4,134,889 shares), positioning the stock -8.89% below its 50-day simple moving average ($0.45) and -51.76% below its 200-day simple moving average ($0.85). Across its 52-week range of $0.35 to $4.00, BEAT sits at the 1.6% percentile with a 14-day RSI of 62.8 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($1.00 to $0.46).
ROARABLE RATING BRIEF • RQD 42/100 (D-)
✓ SEC XBRL & RQD VERIFIED
BEAT — Heartbeam Inc.: What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31
1. Roarable Rating Brief: What This Means to a Prospective Investor
Heartbeam Inc. (BEAT) earns a live Roarable RQD composite score of 42/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $0.41 (-25.64% 1D, market capitalization $31.0M).
- Fundamental Cash Engine (7/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of —.
- Whale 13F & Options Flow (11/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (9/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.
2. Business Model, Unit Margins & SEC Financial Trajectory
Heartbeam Inc. (BEAT) is a NASDAQ-listed issuer in the Health Care sector, operating in the Medical/Dental Instruments industry..0B in that section, while the market data section reports $30.4M.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Heartbeam Inc. (BEAT) reported $59.2M in annual revenue (up from $55.7M in FY2024, +6.3% YoY) and -$21.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($42.9M revenue, -$14.6M net income) through FY2025, BEAT scaled operating cash flow to -$14.0M and free cash flow to -$14.6M, backed by $5.8M in total assets against $0 in total debt.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (D- • RQD 42/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 11/20. With Fundamental Cash Engine at 7/20 and Institutional Whale Flow at 11/20, sustained execution supports upside toward the upper end of the $0.35 – $4.00 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
Operating in Medical/Dental Instruments (Health Care), BEAT carries a macro regime beta of 1.00 and gross margin of —.
- Key Question #1: Can BEAT sustain or expand its — operating margin and -35.0% ROIC against Medical/Dental Instruments peers over the next 4 quarters?
- Key Question #2: Following FY2025 revenue of $59.2M and free cash flow of -$14.6M, how will capital allocation balance growth reinvestment against $0 in total debt?
- Key Question #3: How sensitive is BEAT's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?
BEAT Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Heartbeam Inc. (BEAT) • Click "Debate This Headline" to argue it in the Roar Pit below
🟢 CATALYST Investing.com • 22h ago
HeartBeam stock soars on FDA breakthrough designation Investing.com report covering Heartbeam Inc. (BEAT) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Stocktwits • 1d ago
HeartBeam Inc (BEAT) Profile, Company FAQs & Facts, Industry, Sector, Employee Strength Stocktwits report covering Heartbeam Inc. (BEAT) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE ChartMill • 1d ago
Monday's session: gap up and gap down stocks ChartMill report covering Heartbeam Inc. (BEAT) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 1d ago
HeartBeam Receives FDA Breakthrough Device Designation for Heart Attack Assessment Yahoo Finance report covering Heartbeam Inc. (BEAT) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST www.marketscreener.com • 1d ago
3 Stocks BEAT, MOBX, PRSO Now: FDA Breakthrough, Rare Earths and Military Drones Drive Catalysts www.marketscreener.com report covering Heartbeam Inc. (BEAT) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
FDA grants HeartBeam technology a breakthrough designation for assessing suspected heart attacks outside hospitals. Stock Titan report covering Heartbeam Inc. (BEAT) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Investing.com • 1d ago
Why is Heartbeam stock surging today? Investing.com report covering Heartbeam Inc. (BEAT) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Investing.com • 1d ago
Heartbeam stock rating held at Neutral by H.C. Wainwright on FDA news Investing.com report covering Heartbeam Inc. (BEAT) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
BEAT Bull vs. Bear Conversation Board — What's Your Call at $0.41?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON BEAT 🐻 33% BEARISH CONVICTION
DE DeltaGamma_99 RQD DEBATE OPENER • Options Flow Specialist 🐂 BULLISH
🎯 Target: $0.64 (+16.4%)
📌 Pinned Debate BEAT (D- • RQD 42/100) operating leverage in Medical/Dental Instruments is mispriced at $0.55
Picked up a starter position in BEAT in my $100K Virtual Cash book at $0.55. BEAT (D- • RQD 42/100) operating leverage in Medical/Dental Instruments is mispriced at $0.55. Trading inside a $0.35–$4.00 52-week range with 0.0% FCF yield gives solid downside support if Medical/Dental Instruments multiples expand this quarter.
ArenaChamp_24 🐂 BULL
@ForensicBear Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Medical/Dental Instruments. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.
FO ForensicBear RQD DEBATE OPENER • 10-K Footnote Auditor 🐻 BEARISH
🎯 Target: $0.47 (-14.5%)
Spot @ $0.55 Negative ROIC of -35%, zero FCF yield, and an FY 2025 FCF of -$14.6M against $4.4M cash point to a balance sheet with limited cushion.
Careful chasing BEAT at $0.55. Negative ROIC of -35%, zero FCF yield, and an FY 2025 FCF of -$14.6M against $4.4M cash point to a balance sheet with limited cushion.. Gross margin is 0.0%, but operating margin is 0.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $0.47 on multiple compression.